Metformin: Mechanisms and Expanding Therapeutic Uses
The biochemical pathways of metformin, its main use in the treatment of diabetes, and possible uses in the treatment of other metabolic and age-related diseases are investigated in this review.
Introduction to Metformin
Widely used as the first-line pharmacological treatment for type 2 diabetic mellitus (T2DM), metformin is a member of the biguanide class of drugs. Its main mechanism of action is the lowering of hepatic glucose generation, increase of insulin sensitivity, and improvement of peripheral glucose usage, which taken together help to produce lower blood glucose levels (Bolde, 2024; Sanchez‐Rangel & Inzucchi, 2017). initially synthesized in 1922, the medication was initially presented for human usage in 1957 in line with the groundbreaking research of Jean Sterne. Although it has been in great usage in Europe and other areas before to that, its popularity exploded once it was approved in the United States in 1994 (Sanchez‐Rangel & Inzucchi, 2017; Bai & Chen, 2021).
Numerous studies support metformin’s well-documented ability to lower T2DM by improving glycemic control and therefore lowering the risk of diabetes-related complications (Li et al., 2021; Liu et al., 2012). Apart from its antidiabetic properties, metformin has been linked to weight loss, hence it is especially helpful for obese patients with insulin resistance (Lentferink et al., 2018; Yanovski et al., 2011). Especially in populations where obesity is a major concern, this double action of glycemic control and weight management emphasizes its relevance as a first-line therapy (Ruan et al., 2022).
Originally taken from the plant Galega officinalis, sometimes known as French lilac (S Sanchez-Rangel & Inzucchi, 2017), metformin chemically is a synthetic derivative of guanidine. Its structure enables it to have several effects on metabolic pathways, including the activation of AMP-activated protein kinase (AMPK), which is absolutely important for cellular energy balance (Song et al., 2021; Ala & Ala, 2020). This activation reduces hepatic gluconeogenesis and increases the glucose absorption by peripheral tissues, thereby improving the general insulin sensitivity (Bolde, 2024; Song et al., 2021).
Because of its proven efficacy, safety profile, and extra advantages like weight loss, metformin is essentially the pillar of treatment for T2DM. Discovering it and then using it clinically has had a major effect on diabetes treatment, therefore it is a necessary part of treatment plans for millions of patients all over.
Mechanisms of Action
Widely used for type 2 diabetic mellitus (T2DM), metformin acts therapeutively by numerous linked processes that increase insulin sensitivity, lower hepatic glucose production, and change cellular metabolism. Appreciating how metformin helps to achieve glycemic control and metabolic health depends on an awareness of these processes.
Among metformin’s main effects are those on insulin sensitivity in peripheral tissues, especially in muscle and adipose tissue. The activation of AMP-activated protein kinase (AMPK), a fundamental control of cellular energy homeostasis, mostly mediates this action. AMPK increases the translocation of glucose transporter type 4 (GLUT4) to the cell membrane, therefore enabling glucose access into cells and hence activating AMPK (LaMoia & Shulman, 2020). Furthermore important for lowering hepatic glucose production (Ouyang et al., 2011) is the inhibition of gluconeogenic gene expression in the liver brought on by AMPK activation. The benefit of metformin in decreasing blood glucose levels is derived from this dual action: boosting glucose absorption in peripheral tissues while concurrently suppressing glucose generation in the liver.
Metformin dramatically lowers glucose generation in the liver by several routes. One suggested mechanism is the suppression of mitochondrial respiratory chain complex I, which lowers ATP synthesis and raises the AMP/ATP ratio. This change in energy status triggers AMPK, which downregulates important gluconeogenic enzymes like glucose-6-phosphatase (LaMoia & Shulman, 2020; Ouyang et al., 2011), hence suppressing gluconeogenesis. Moreover, metformin has been demonstrated to reduce the activity of glycerol-3-phosphate dehydrogenase, a fundamental enzyme in gluconeogenesis, hence lowering hepatic glucose output (Cao et al., 2014).
Moreover, the effects of metformin on cellular metabolism go beyond control of glucose. It has been seen to affect lipid metabolism by lowering hepatic lipid accumulation, hence improving insulin sensitivity (LaMoia & Shulman, 2020). In the framework of non-alcoholic fatty liver disease (NAFLD), where metformin’s capacity to reduce liver fat accumulation may help patients with T2DM (LaMoia & Shulman, 2020) this is especially pertinent. Furthermore underlining metformin’s multifarious importance in metabolic health are its impacts on the gut flora and its ability to change inflammatory pathways (Mahmood, 2021).
By a complex interaction of processes involving AMPK activation, inhibition of gluconegenic pathways, and modification of lipid metabolism, metformin increases insulin sensitivity and lowers hepatic glucose production overall. These activities not only help to control T2DM but also show their possible advantages in more general metabolic settings.
Clinical Applications and Future Directions
Long recognized as the first-line treatment for type 2 diabetic mellitus (T2DM), metformin’s efficacy in enhancing glycemic control and good safety profile help to explain why. Apart from its function in the control of diabetes, continuous studies are investigating metformin’s possible advantages in several other diseases, therefore stressing its adaptability as a therapeutic agent.
Within the framework of diabetes therapy, metformin’s main action is increasing insulin sensitivity and lowering hepatic glucose generation, which taken together provide better glycemic control (Ahmad et al., 2020; Zilov et al., 2019). Usually in concert with lifestyle changes, clinical recommendations consistently recommend metformin as the first pharmacotherapy for T2DM (Abdelgawad & Bakri, 2019; Alhaji, 2022). Particularly helpful for patients with concomitant cardiovascular illness (Griffine et al., 2017), its use has been linked to a reduced risk of cardiovascular events. Furthermore, given that metformin does not cause weight gain, a common side effect of many other antidiabetic drugs, its weight-neutral profile is beneficial—especially for overweight individuals (Ahmad et al., 2020; Zilov et al., 2019).
Emerging data points to possible benefits for metformin outside of controlling diabetes. Studies have revealed, for example, a possible function for metformin in treatment and prevention of cancer. Studies of males with benign prostatic hyperplasia have indicated that metformin might lower their risk of prostate cancer. Kuo et al. (2019) and might also be linked with higher survival rates in patients with breast cancer (Tharakan et al., 2020). Thought to be contributing to the drug’s anticancer properties is its capacity to alter metabolic paths including the mammalian target of rapamycin (mTOR) pathway (Triggle et al., 2022). Moreover, metformin has been looked at for its use in urologic oncology; studies point to it perhaps helping to control some urologic tumors (Sayyid & Fleshner, 2016).
Apart from its uses in oncology, metformin is being investigation for control of gestational diabetes. Providing a workable substitute for insulin treatment, high dosages of metformin have been found to be successful in lowering blood glucose levels during pregnancy (Garbarino et al., 2019; innocent et al., 2022). Given the rising incidence of gestational diabetes and the necessity of efficient therapies reducing dangers to mother and child, this is especially crucial.
Furthermore under active study is how metformin affects cardiovascular health. Use of metformin is linked, according a meta-analysis, to a lower risk of cardiovascular disease in T2DM patients (Griffin et al., 2017). This cardioprotective effect suggests that metformin may have more general consequences for controlling cardiovascular risk factors (Zilov et al., 2019), independent of its ability to reduce glucose levels.
Innovative drug delivery systems are being developed to maximize metformin therapy, so improving its bioavailability and targeting particular metabolic pathways as research on this continues (Abbasi, 2024). These developments might extend the uses of metformin outside of diabetes control, therefore addressing unmet medical requirements in other clinical environments.
With further studies revealing its possible advantages in cancer prevention, gestational diabetes, and cardiovascular health, metformin is ultimately still the pillar of treatment for T2DM. Metformin will probably become more and more important in a greater range of treatment settings as our knowledge of this multifarious medicine develops.
References:
Ala, M. and Ala, M. (2021). Metformin for cardiovascular protection, inflammatory bowel disease, osteoporosis, periodontitis, polycystic ovarian syndrome, neurodegeneration, cancer, inflammation and senescence: what is next?. Acs Pharmacology & Translational Science, 4(6), 1747-1770. https://doi.org/10.1021/acsptsci.1c00167
Bai, B. and Chen, H. (2021). Metformin: a novel weapon against inflammation. Frontiers in Pharmacology, 12. https://doi.org/10.3389/fphar.2021.622262
Bolde, D. (2024). Metformin: an overview. World Journal of Biology Pharmacy and Health Sciences, 18(3), 186-198. https://doi.org/10.30574/wjbphs.2024.18.3.0331
Lentferink, Y., Knibbe, C., & Vorst, M. (2018). Efficacy of metformin treatment with respect to weight reduction in children and adults with obesity: a systematic review. Drugs, 78(18), 1887-1901. https://doi.org/10.1007/s40265-018-1025-0
Li, X., Celotto, S., Pizzol, D., Gasevic, D., Ji, M., Barnini, T., … & Demurtas, J. (2021). Metformin and health outcomes: an umbrella review of systematic reviews with meta‐analyses. European Journal of Clinical Investigation, 51(7). https://doi.org/10.1111/eci.13536
Liu, S., Tu, Y., Chien, M., & Chien, K. (2012). Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta‐analysis. Diabetes Obesity and Metabolism, 14(9), 810-820. https://doi.org/10.1111/j.1463-1326.2012.01606.x
Ruan, G., Yuan, S., Aiju, L., Mo, Y., Yuan, Q., Guo, D., … & Ding, C. (2022). Can metformin relieve tibiofemoral cartilage volume loss and knee symptoms in overweight knee osteoarthritis patients? study protocol for a randomized, double-blind, and placebo-controlled trial. BMC Musculoskeletal Disorders, 23(1). https://doi.org/10.1186/s12891-022-05434-2
Sanchez‐Rangel, E. and Inzucchi, S. (2017). Metformin: clinical use in type 2 diabetes. Diabetologia, 60(9), 1586-1593. https://doi.org/10.1007/s00125-017-4336-x
Song, P., Hwang, J., Park, H., Kim, K., Son, H., Kim, Y., … & Lee, K. (2021). Therapeutic applications of type 2 diabetes mellitus drug metformin in patients with osteoarthritis. Pharmaceuticals, 14(2), 152. https://doi.org/10.3390/ph14020152
Yanovski, J., Krakoff, J., Salaita, C., McDuffie, J., Kozlosky, M., Sebring, N., … & Calis, K. (2011). Effects of metformin on body weight and body composition in obese insulin-resistant children. Diabetes, 60(2), 477-485. https://doi.org/10.2337/db10-1185
Cao, J., Meng, S., Chang, E., Beckwith-Fickas, K., Xiong, L., Cole, R., … & He, L. (2014). Low concentrations of metformin suppress glucose production in hepatocytes through amp-activated protein kinase (ampk)*. Journal of Biological Chemistry, 289(30), 20435-20446. https://doi.org/10.1074/jbc.m114.567271
LaMoia, T. and Shulman, G. (2020). Cellular and molecular mechanisms of metformin action. Endocrine Reviews, 42(1), 77-96. https://doi.org/10.1210/endrev/bnaa023
Mahmood, S. (2021). Mechanisms of action of metformin. https://doi.org/10.5772/intechopen.99189
Ouyang, J., Parakhia, R., & Ochs, R. (2011). Metformin activates amp kinase through inhibition of amp deaminase. Journal of Biological Chemistry, 286(1), 1-11. https://doi.org/10.1074/jbc.m110.121806
Abbasi, M. (2024). Advances in metformin‐delivery systems for diabetes and obesity management. Diabetes Obesity and Metabolism, 26(9), 3513-3529. https://doi.org/10.1111/dom.15759
Abdelgawad, F. and Bakri, G. (2019). Serum vitamin b12 and homocysteine levels in type 2 diabetic patients with and without metformin therapy. Journal of Biomedical Science and Engineering, 12(12), 557-570. https://doi.org/10.4236/jbise.2019.1212046
Ahmad, E., Sargeant, J., Zaccardi, F., Khunti, K., Webb, D., & Davies, M. (2020). Where does metformin stand in modern day management of type 2 diabetes?. Pharmaceuticals, 13(12), 427. https://doi.org/10.3390/ph13120427
Alhaji, J. (2022). Vitamin b12 deficiency in patients with diabetes on metformin: arab countries. Nutrients, 14(10), 2046. https://doi.org/10.3390/nu14102046
Garbarino, V., Santos, T., Nelson, A., Zhang, W., Smolik, C., Javors, M., … & Gould, G. (2019). Prenatal metformin exposure or organic cation transporter 3 knock-out curbs social interaction preference in male mice. Pharmacological Research, 140, 21-32. https://doi.org/10.1016/j.phrs.2018.11.013
Griffin, S., Leaver, J., & Irving, G. (2017). Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes. Diabetologia, 60(9), 1620-1629. https://doi.org/10.1007/s00125-017-4337-9
Innocent, D., Vasavada, A., & Uwaezuoke, A. (2022). Metformin versus glyburide in the management of gestational diabetes; a systematic review and meta-analysis. International Journal of Science and Healthcare Research, 7(3), 336-344. https://doi.org/10.52403/ijshr.20220746
Kuo, Y., Sung, F., Hsieh, P., Chang, H., Wu, K., & Wu, H. (2019). Metformin reduces prostate cancer risk among men with benign prostatic hyperplasia: a nationwide population‐based cohort study. Cancer Medicine, 8(5), 2514-2523. https://doi.org/10.1002/cam4.2025
Sayyid, R. and Fleshner, N. (2016). Potential role for metformin in urologic oncology. Investigative and Clinical Urology, 57(3), 157. https://doi.org/10.4111/icu.2016.57.3.157
Tharakan, S., Zimmerman, B., Ru, M., Blanter, J., Cascetta, K., & Tiersten, A. (2020). Diabetes and metformin association with recurrence score in a large oncotype database of breast cancer patients. Oncology, 98(8), 589-592. https://doi.org/10.1159/000506076
Triggle, C., Mohammed, I., Bshesh, K., Marei, I., Ye, K., Ding, H., … & Hill, M. (2022). Metformin: is it a drug for all reasons and diseases?. Metabolism, 133, 155223. https://doi.org/10.1016/j.metabol.2022.155223
Zilov, A., Abdelaziz, S., Alshammary, A., Zahrani, A., Amir, A., Khalil, S., … & Paruk, I. (2019). Mechanisms of action of metformin with special reference to cardiovascular protection. Diabetes/Metabolism Research and Reviews, 35(7). https://doi.org/10.1002/dmrr.3173
